• About us
  • Privacy Policy
  • Contact us
Neo Science Hub
ADVERTISEMENT
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
Neo Science Hub
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

India’s anti-obesity drug market has expanded more than four times over the past five years

Raja Aditya by Raja Aditya
2 years ago
in Healthcare & Medicine, Science News
0
anti-obesity

India's anti-obesity drug market has expanded more than four times over the past five years | Neo Science Hub

India’s fight against obesity is gaining traction as the anti-obesity drug market has experienced explosive growth over the past five years, expanding more than fourfold to reach ₹576 crore by March 2025. This remarkable increase is primarily attributed to rising lifestyle diseases paired with a newfound willingness among consumers to invest in weight-loss treatments.

The growth of the anti-obesity drug segment is underscored by the significant market presence of semaglutide, marketed under the brand name Rybelsus by Danish pharmaceutical giant Novo Nordisk. This oral medication currently holds a commanding 69% share, generating ₹397 crore in sales—a notable jump from just ₹11 crore in March 2022. Semaglutide functions by mimicking a hormone that promotes feelings of fullness, therefore aiding in weight management.

The burgeoning acceptance of weight-loss medications among the Indian populace is also bolstered by the recent introduction of new treatment options. Eli Lilly’s Mounjaro (tirzepatide), a once-weekly injectable drug, has garnered attention for its efficacy in reducing body weight by up to 20%. Priced at around ₹3,500 per injection, Mounjaro has emerged as a financially feasible option for many looking to combat obesity.

As adults in India increasingly grapple with obesity—affecting nearly 100 million individuals—this segment is crucial not only for personal health but also for addressing related comorbid conditions such as type 2 diabetes and cardiovascular disease.

While semaglutide and tirzepatide remain at the forefront, other medications are also making their mark on the market. Drugs such as orlistat, dulaglutide, and liraglutide are notable players, with market valuations of ₹72 crore and ₹34 crore, respectively. These alternatives further enhance the treatment landscape, providing patients with various choices based on their specific weight management needs and medical histories.

Despite the increased popularity and efficacy of these medications, healthcare professionals emphasize that they should be paired with lifestyle modifications. Sustainable weight loss often necessitates a combination of medication and behavioural changes, including dietary management and increased physical activity.

Experts assert that medications alone cannot solve the obesity epidemic. Dr. Anjali Mehta, a leading endocrinologist in Mumbai, states, “While these drugs are effective, they are not a standalone solution. Encouraging a healthy lifestyle is paramount for achieving long-term results.”

-Raja Aditya

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Telegram (Opens in new window) Telegram
  • Email a link to a friend (Opens in new window) Email
Tags: anti-obesity drug marketfeaturedLifestyle Diseasessciencenewssemaglutide
Raja Aditya

Raja Aditya

Associate Editor for Neo Science Hub Magazine

Other Posts

Young maize in paired rows on raised beds with water in the furrows between them

Lifting the Crop Off the Floor: Why Raised Beds Are Gaining Ground in a Water-Short Country

November 15, 2026
1
Trays of green and purple microgreens beside a field being sprayed

Small Leaves, Small Particles: Microgreens Have the Evidence. Nano-Urea Is Still Earning It

November 15, 2026
3

A Crore and a Half Recharge Pits Later: What India’s Water Reforms Can, and Cannot, Teach the Global South

A Purple Broccoli That Seeds in Delhi and a Sponge Gourd That Shrugs Off a Virus

Fourteen Seconds to 241 km/h and Back: What a Runway Test Says About Where Car Performance Now Lives

An Aeroplane on a Helipad: What Electra’s Manhattan Landing Proves, and What It Does Not

After the Space Station: NASA Opens the Contest to Become a Tenant in Orbit

At 94, the Air Force Counts Its Squadrons, and Waits for an Engine India Can Call Its Own

Next Post
Ozempic

Beyond Weight Loss: Can Ozempic Enhance Brain Function and Reduce Dementia Risk?

Subscribe to Us

Latest Articles

Cross-section of a human eye with the optic nerve head highlighted

FDA Orders Eye-Risk Warnings on All GLP-1 Drugs, From Ozempic to Mounjaro

November 12, 2026
7

Delhi’s Diwali, Measured: Firecrackers Drove 71% of Fine Particles, Lead Hit 20 Times the Limit, and the Worst Readings Went Missing

Global Carbon Budget 2026: The World’s Fossil Emissions Dip, India’s Rise 4.4%, and the 1.5 °C Budget Is Nearly Spent

A New Kind of Blood Thinner: FDA Approves Asundexian to Prevent Repeat Strokes

Andhra Pradesh Opens the Door to Small Nuclear Reactors, Robots and Giga-Scale AI Data Centres — With the Details Still to Come

“Off the Charts”: WMO Tells COP31 That 2026 Is Among the Hottest Years on Record as a Record El Niño Builds

  • Advertise
  • Terms and Conditions
  • Privacy Policy
  • Refund Policy
  • Contact
For Feedback : Email Us

Copyrights © 2025 Neo Science Hub

No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Copyrights © 2025 Neo Science Hub

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist